Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,952 public trials 630 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Active, Not Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Arkansas Urology Little Rock, Arkansas, United States
  • Genesis Research LLC 1 Los Alamitos, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
View all 123 locations
View Trial Details
Active, Not Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • VA Long Beach Health Care System Long Beach, California, United States
  • Genesis Research, LLC - West Coast Urology Los Alamitos, California, United States
View all 240 locations
View Trial Details
Active, Not Recruiting

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

NCT01888198

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney Diseases, +9 more
Locations
  • University of California, Los Angeles Los Angeles, California, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

NCT03595124

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +18 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 267 locations
View Trial Details
Active, Not Recruiting

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

NCT03244384

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Localized Renal Pelvis and Ureter Urothelial Carcinoma, +19 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 915 locations
View Trial Details
Active, Not Recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +80 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 174 locations
View Trial Details
Active, Not Recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +9 more
Locations
  • University of South Alabama, Mitchell Cancer Institute ( Site 1582) Mobile, Alabama, United States
  • CARTI Cancer Center ( Site 1577) Little Rock, Arkansas, United States
  • St. Joseph Heritage Healthcare ( Site 0046) Fullerton, California, United States
  • Scripps MD Anderson ( Site 0010) La Jolla, California, United States
View all 242 locations
View Trial Details

Related conditions